Axsome Therapeutics (AXSM) Stock Price, News & Analysis

Company Overview

Axsome Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for central nervous system (CNS) disorders. The company focuses on small-molecule drugs designed to address unmet medical needs in areas such as depression, migraine, narcolepsy and fibromyalgia. Axsome employs a precision medicine approach, leveraging pharmacologic innovation to target underlying mechanisms of disease and improve patient outcomes.

Axsome’s pipeline includes several late-stage and approved product candidates. AXS-05, a first-in-class oral investigational therapy combining dextromethorphan and bupropion, received U.S. Food and Drug Administration (FDA) approval for the treatment of major depressive disorder in 2021 and for agitation associated with Alzheimer’s disease. AXS-07, a combination of meloxicam and rizatriptan for acute migraine, gained FDA approval in 2023. The company is also advancing AXS-12 for narcolepsy and idiopathic hypersomnia under FDA review, as well as AXS-14, a proprietary formulation of esreboxetine, targeting fibromyalgia and related chronic pain conditions.

Founded in 2012 and headquartered in New York City, Axsome Therapeutics conducts its research and development activities primarily in the United States. The company’s leadership team is led by President and Chief Executive Officer Herriot Tabuteau, M.D., who brings extensive experience in neurologic and psychiatric drug development. Under his guidance, Axsome has advanced multiple clinical programs through crucial regulatory milestones and continues to collaborate with academic institutions and contract research organizations to support its growth strategy.

Key Stats

• Today's Range: $222.33 to $231.00
• 50-Day Range: $154.12 to $223.06
• 52-Week Range: $96.09 to $234.29
• Volume: 1.02 million shs
• Average Volume: 882,597 shs
• Market Capitalization: $11.47 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $251.89
• Consensus Rating: Moderate Buy

Axsome Therapeutics Stock Analysis - MarketRank™

Axsome Therapeutics scored higher than 63% of companies evaluated by MarketBeat, and ranked 282nd out of 856 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Axsome Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.90, and is based on 1 strong buy rating, 18 buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

Axsome Therapeutics has a consensus price target of $251.89, representing about 12.9% upside from its current price of $223.06.

Amount of Analyst Coverage

Axsome Therapeutics has been the subject of 18 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Axsome Therapeutics are expected to grow in the coming year, from ($1.05) to $5.58 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Axsome Therapeutics is -59.80, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Axsome Therapeutics is -59.80, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Axsome Therapeutics has a P/B Ratio of 127.46. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

6.74% of the float of Axsome Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Axsome Therapeutics has a short interest ratio ("days to cover") of 4.55.

Change versus previous month

Short interest in Axsome Therapeutics has recently decreased by 5.36%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Axsome Therapeutics does not currently pay a dividend.

Dividend Growth

Axsome Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 3.4 / 5
• News Sentiment: 0.47

News Sentiment

Axsome Therapeutics has a news sentiment score of 0.47. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 48 news articles for Axsome Therapeutics this week, compared to 8 articles on an average week.

Search Interest

42 people have searched for AXSM on MarketBeat in the last 30 days. This is an increase of 147% compared to the previous 30 days.

MarketBeat Follows

12 people have added Axsome Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 1,100% compared to the previous 30 days.

Company Ownership

• Score: 2.1 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Axsome Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $12,205,662.00 in company stock.

Percentage Held by Insiders

20.60% of the stock of Axsome Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

81.49% of the stock of Axsome Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

AXSM Stock Analysis - Frequently Asked Questions

How have AXSM shares performed this year?

Axsome Therapeutics' stock was trading at $182.64 at the beginning of 2026. Since then, AXSM stock has increased by 22.1% and is now trading at $223.06.

How were Axsome Therapeutics' earnings last quarter?

Axsome Therapeutics, Inc. (NASDAQ:AXSM) announced its quarterly earnings data on Monday, May, 4th. The company reported ($1.26) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.85) by $0.41. The company's quarterly revenue was up 57.4% on a year-over-year basis.
Read the conference call transcript.

When did Axsome Therapeutics IPO?

Axsome Therapeutics (AXSM) raised $52 million in an initial public offering on Thursday, November 19th 2015. The company issued 4,300,000 shares at $11.00-$13.00 per share. Ladenburg Thalmann and Cantor Fitzgerald & Co. acted as the underwriters for the IPO and Brean Capital was co-manager.

Who are Axsome Therapeutics' major shareholders?

Top institutional shareholders of Axsome Therapeutics include Assenagon Asset Management S.A. (1.69%), Pictet Asset Management Holding SA (0.81%), Principal Financial Group Inc. (0.68%) and Bank of New York Mellon Corp (0.40%). Insiders that own company stock include Roger Jeffs, Mark Coleman, Nick Pizzie, Mark E Saad, Ari Maizel, Herriot Tabuteau, Mark L Jacobson and Hunter R Murdock.
View institutional ownership trends.

How do I buy shares of Axsome Therapeutics?

Shares of AXSM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Axsome Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Axsome Therapeutics investors own include Humana (HUM), American Water Works (AWK), Voyager Therapeutics (VYGR), Waste Connections (WCN), The RMR Group (RMR), DiamondRock Hospitality (DRH) and

Company Calendar

• Last Earnings: 5/04/2026
• Today: 5/05/2026
• Bank of America Global Healthcare Conference 2026: 5/12/2026
• RBC Capital Markets Global Healthcare Conference 2026: 5/19/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:AXSM
• CIK: 1579428
• Web: axsome.com
• Phone: (212) 332-3241
• Fax: 212-320-0245
• Employees: 380
• Year Founded: 2012

Price Target and Rating

• Average Price Target for Axsome Therapeutics: $251.89
• High Price Target: $310.00
• Low Price Target: $176.00
• Potential Upside/Downside: +12.9%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.90
• Research Coverage: 21 Analysts

Profitability

• EPS (Trailing Twelve Months): ($3.69)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$183.17 million
• Net Margins: -26.59%
• Pretax Margin: -28.77%
• Return on Equity: -246.90%
• Return on Assets: -29.04%

Debt

• Debt-to-Equity Ratio: 1.38
• Current Ratio: 1.55
• Quick Ratio: 1.48

Sales & Book Value

• Annual Sales: $638.50 million
• Price / Sales: 17.97
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.75 per share
• Price / Book: 127.46

Miscellaneous

• Outstanding Shares: 51,440,000
• Free Float: 40,843,000
• Market Cap: $11.47 billion
• Optionable: Optionable
• Beta: 0.59